Gemcitabine and CARBOplatin (AUC2) Therapy - 21 days. NCCP National SACT Regimen. HSE.
Regulatory approval published by the Health Service Executive.
Citation
Regulatory approvals
Approved indications from this document for cancer drugs containing at least one biomarker.
| Indication | Statements |
|---|---|
| Treatment of locally recurrent metastatic triple negative breast cancer. | 1 |
Therapeutic response
Precision oncology relationships for therapeutic response derived from this document.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| HSE (1) | ER negative, HER2-negative, PR negative | Invasive Breast Carcinoma | Carboplatin, Gemcitabine |